ANGLE (OTCMKTS:ANPCY) vs. Nautilus Biotechnology (NASDAQ:NAUT) Head to Head Analysis

Nautilus Biotechnology (NASDAQ:NAUT) and ANGLE (OTCMKTS:ANPCY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nautilus Biotechnology and ANGLE, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1	0	1	0	2.00
ANGLE	0	0	0	0	0.00

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 356.99%. Given Nautilus Biotechnology’s stronger consensus rating and higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than ANGLE.

Valuation and Earnings

This table compares Nautilus Biotechnology and ANGLE”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	$10,000.00	11,138.63	-$59.00 million	($0.45)	-1.95
ANGLE	N/A	N/A	N/A	C($0.48)	-0.14

ANGLE has lower revenue, but higher earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nautilus Biotechnology and ANGLE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
ANGLE	N/A	N/A	N/A

Institutional and Insider Ownership

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nautilus Biotechnology beats ANGLE on 7 of the 10 factors compared between the two stocks.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.